AI assistant
Sending…
EBOS GROUP LIMITED — Director's Dealing 2015
May 24, 2015
64813_rns_2015-05-24_adc751ac-a7d1-411f-8b39-1bf89ccbb35b.pdf
Director's Dealing
Open in viewerOpens in your device viewer
==> picture [98 x 27] intentionally omitted <==
Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
| To NZX Limited; and | ||
|---|---|---|
| Name of listed issuer: | EBOS GroupLimited | |
| Date this disclosure made: | 25-May-15 | |
| Date of last disclosure: | 24-Oct-14 | |
| Director or senior managergiving disclosure | ||
| Full name(s): | Dennis Condon Doherty | |
| Name of listed issuer: | EBOS GroupLimited | |
| Name of related body corporate (if applicable): | N/A | |
| Position held in listed issuer: | FormerCFO | |
| Summary of acquisition or disposal of relevant interest (excluding specified derivatives) Class of affected quoted financial products: Ordinary shares Nature of the affected relevant interest(s): Beneficial For that relevant interest- Number held in class before acquisition or disposal: 92,195 Number held in class after acquisition or disposal: 195 |
||
| Class of affected quoted financial products: | Ordinary shares | |
| Nature of the affected relevant interest(s): | Beneficial | |
| For that relevant interest- | ||
| Number held in class before acquisition or disposal: | 92,195 | |
| Number held in class after acquisition or disposal: | 195 | |
| Current registered holder(s): | Dennis Condon Doherty | |
| Registered holder(s)once transfers are registered: | Dennis Condon Doherty | |
| Summary of acquisition or disposal of specified derivatives relevant interest (if applicable) Type of affected derivative: Class of underlyingfinancialproducts: Details of affected derivative- The notional value of the derivative (if any) or the notional amount of underlying financial products(if any): A statement as to whether the derivative is cash settled orphysicallysettled: |
||
| The notional value of the derivative (if any) or the notional amount of underlying financial products(if any): |
||
| A statement as to whether the derivative is cash settled orphysicallysettled: | ||
| Maturitydate of the derivative(if any): | ||
| Expirydate of the derivative(if any): | ||
| Theprice specified in the terms of the derivative(if any): | ||
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: |
||
| For that derivative,- Parties to the derivative: If the director or senior manager is not a party to the derivative, the nature of the relevant interestinthe derivative: |
||
| Parties to the derivative: | ||
| If the director or senior manager is not a party to the derivative, the nature of the relevant interestinthe derivative: |
||
| Details of transactions giving rise to acquisition or disposal | ||
| Total numberoftransactions towhich noticerelates: | 2 | |
| 20-May-15 | ||
| Sale ofordinary shares | ||
| N/A | ||
| NZD868,838.72 | ||
| 1 |
| If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details— |
||
|---|---|---|
| Whether relevantinterestswere acquired ordisposed ofduring a closed period: | No | |
| Whether prior written clearance was provided to allow the acquisition or disposal to proceed duringthe closedperiod: |
||
| Date of theprior written clearance(if any): |
Summary of other relevant interests after acquisition or disposal:
| Class ofquotedfinancialproducts: | |||
|---|---|---|---|
| Nature of relevantinterest: | |||
| _For that relevant interest,- _ | |||
| Number heldinclass: | |||
| Currentregisteredholder(s): | |||
| For a derivative relevant interest,- | |||
| Type ofderivative: | |||
| Details of derivative,- | |||
| The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): |
|||
| A statement as to whether the derivative is cash settled or physically settled: | |||
| Maturity date of the derivative (if any): | |||
| Expiry date of the derivative (if any): | |||
| The price's specified terms (if any): | |||
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlyingfinancialproducts: |
|||
| For that derivative relevant interest,- | |||
| Parties to the derivative: | |||
| If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: |
|||
| Certification | 25-May-15 Sarah Turner |
||
| I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made. |
|||
| Signature of director or officer: | |||
| Date of signature: | |||
| or | |||
| Signature of person authorised to sign on behalf of director or officer: | |||
| Date of signature: | |||
| Name and title of authorisedperson: | |||
Notes
Use this form to disclose all the acquisitions and disposals by a director or senior manager of a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must be made within—
(a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or
(b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.
More from EBOS GROUP LIMITED
Share Issue/Capital Change
2026
May 18
Share Issue/Capital Change
2026
May 18
Share Issue/Capital Change
2026
May 17
Share Issue/Capital Change
2026
May 17
Share Issue/Capital Change
2026
May 17
Share Issue/Capital Change
2026
May 17
Capital/Financing Update
2026
May 6
Share Issue/Capital Change
2026
May 5
Capital/Financing Update
2026
May 5
Regulatory Filings
2026
May 1